Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

<h4>Background</h4>Pfs25 and Pvs25, surface proteins of mosquito stage of the malaria parasites P. falciparum and P. vivax, respectively, are leading candidates for vaccines preventing malaria transmission by mosquitoes. This single blinded, dose escalating, controlled Phase 1 study asse...

Full description

Bibliographic Details
Main Authors:	Yimin Wu, Ruth D Ellis, Donna Shaffer, Erica Fontes, Elissa M Malkin, Siddhartha Mahanty, Michael P Fay, David Narum, Kelly Rausch, Aaron P Miles, Joan Aebig, Andrew Orcutt, Olga Muratova, Guanhong Song, Lynn Lambert, Daming Zhu, Kazutoyo Miura, Carole Long, Allan Saul, Louis H Miller, Anna P Durbin
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2008-07-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18612426/?tool=EBI

Similar Items

Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer
by: Long Carole A, et al.
Published: (2007-08-01)

Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission
by: Kelly M. Rausch, et al.
Published: (2023-07-01)

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
by: Kawsar R Talaat, et al.
Published: (2016-01-01)

mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response
by: Puthupparampil V. Scaria, et al.
Published: (2024-01-01)

Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose
by: Wei-Chiao Huang, et al.
Published: (2020-08-01)

Gametocyte carriage of Plasmodium falciparum (pfs25) and Plasmodium vivax (pvs25) during mass screening and treatment in West Timor, Indonesia: a longitudinal prospective study
by: Kosasih, A, et al.
Published: (2021)

Risk factors for patent and sub-patent gametocyte carriage of Plasmodium falciparum (pfs25) and Plasmodium vivax (pvs25) in hypo- to meso-endemic West Timor in Eastern Indonesia
by: Kosasih, AA, et al.
Published: (2019)

Immune System Modulation by the Adjuvants Poly (I:C) and Montanide ISA 720
by: Rodolfo F. Marques, et al.
Published: (2022-06-01)

Comparative study on alginate/chitosan microcapsules and Montanide ISA 61 as vaccine adjuvants in mice.
by: Laice A Silva, et al.
Published: (2024-01-01)

A human antibody epitope map of the malaria vaccine antigen Pfs25
by: Niharika Shukla, et al.
Published: (2023-08-01)

Evaluation of Montanide™ ISA 71 VG adjuvant during profilin vaccination against experimental coccidiosis.
by: Seung I Jang, et al.
Published: (2013-01-01)

1404 MONTANIDE™ ISA 51 VG: open access adjuvant dedicated to therapeutic vaccines
by: Marie-Eve Koziol
Published: (2023-11-01)

New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission
by: Kathleen A. McGuire, et al.
Published: (2017-06-01)

Cancer Vaccination against Extracellular Vimentin Efficiently Adjuvanted with Montanide ISA 720/CpG
by: Karlijn van Loon, et al.
Published: (2022-05-01)

Using Montanide™ ISA 50 V2 as adjuvant for the formulation of the anti-tick Gavac® vaccine
by: Carlos Perez Heredia, et al.
Published: (2017-12-01)

Structural and immunological differences in Plasmodium falciparum sexual stage transmission-blocking vaccines comprised of Pfs25-EPA nanoparticles
by: Nicholas J. MacDonald, et al.
Published: (2023-04-01)

Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.
by: Ruth D Ellis, et al.
Published: (2012-01-01)

Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant Pfs25
by: David C. Kaslow, et al.
Published: (1992-01-01)

Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission.
by: James A Gregory, et al.
Published: (2012-01-01)

Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.
by: Barney S Graham, et al.
Published: (2010-08-01)

Genetic diversity of transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 in Plasmodium vivax isolates from China
by: Siqi Wang, et al.
Published: (2022-12-01)

Evolution of the Transmission-Blocking Vaccine Candidates Pvs28 and Pvs25 in Plasmodium vivax: Geographic Differentiation and Evidence of Positive Selection.
by: Ricardo A Chaurio, et al.
Published: (2016-06-01)

Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25
by: Stephen W. Scally, et al.
Published: (2017-11-01)

Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity.
by: Farrance, C, et al.
Published: (2011)

Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity
by: Farrance, C, et al.
Published: (2011)

A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720.
by: James S McCarthy, et al.
Published: (2011-01-01)

Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice
by: Florian Brod, et al.
Published: (2018-12-01)

Efficacy of SAT2 Foot-and-Mouth Disease Vaccines Formulated with Montanide ISA 206B and Quil-A Saponin Adjuvants
by: Ntungufhadzeni M. Rathogwa, et al.
Published: (2021-09-01)

Preparation and in vivo anti-tumor evaluation of human papillomavirus E7 adjuvanted with Montanide ISA 266 as a vaccine candidate
by: M Mashhadi Abolghasem Shirazi, et al.
Published: (2017-05-01)

Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.
by: Meta Roestenberg, et al.
Published: (2008-01-01)

Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans
by: Marija Zaric, et al.
Published: (2021-09-01)

Peptide data on the disulfide bond analysis of baculovirus produced Pfs25 by LC-MSMS
by: Shwu-Maan Lee, et al.
Published: (2018-06-01)

Evaluation of Four Adjuvant Combinations, IVAX-1, IVAX-2, CpG-1826+Montanide ISA 720 VG and CpG-1018+Montanide ISA 720 VG, for Safety and for Their Ability to Elicit Protective Immune Responses in Mice against a Respiratory Challenge with <i>Chlamydia muridarum</i>
by: Sukumar Pal, et al.
Published: (2023-06-01)

Studies on humoral immunity in dogs after use of rabies inactivated vaccines formulated with Montanide ISA 70 VG and GEL 01 adjuvants
by: A. N. Balashov, et al.
Published: (2020-03-01)

Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques
by: Walraven Vanessa, et al.
Published: (2011-07-01)

Development of a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50 V and determination of its protective efficacy against acute toxoplasmosis
by: Esra Atalay Şahar, et al.
Published: (2020-07-01)

Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.
by: Ruth D Ellis, et al.
Published: (2010-01-01)

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial
by: Hans de Graaf, et al.
Published: (2021-07-01)

LigA formulated in AS04 or Montanide ISA720VG induced superior immune response compared to alum, which correlated to protective efficacy in a hamster model of leptospirosis
by: Vivek P. Varma, et al.
Published: (2022-10-01)

Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults.
by: Jinhong Hu, et al.
Published: (2008-01-01)